Aura Biosciences Risk Report

📜 Innovation & R&D

Aura Biosciences is at the forefront of cancer treatment development, specifically targeting choroidal melanoma and bladder cancer. The company is leveraging novel drugs and advance-stage trials to make significant impacts in the precision cancer treatment sector. With $151 million extended cash runway reported, they're poised for continued advancements and trial expansions.

• Positive results from phase 1 trial of bel-sar in non-muscle-invasive bladder cancer were presented 🗓 March 24, 2025.
• Aura announced additional data from ongoing phase 1 trial in bladder cancer as a late-breaking abstract at the European Association of Urology Congress 🗓 March 3, 2025.
• They secured $75 million in funding for precision cancer treatment 🗓 May 15, 2025.
• Their virus-based drug eradicated tumors in 4 out of 5 low-grade bladder cancer patients 🗓 October 17, 2024.
• Fast track designation granted by FDA for a new therapy for non-muscle invasive bladder cancer 🗓 July 7, 2022.